Skip to main content

Table 1 Baseline patient demographics, characteristics, and medical history

From: Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results

  FPV/r + ABC/3TC (n = 51) EFV + ABC/3TC (n = 50)
Median age, years (range) 34.0 (18–79) 33.5 (19–55)
Female, n (%) 16 (31%) 16 (32%)
Race/ethnicity, n (%)   
 African American, non-Hispanic 29 (57%) 33 (66%)
 Hispanic, non-African American 18 (35%) 13 (26%)
 African American and Hispanic 3 (6%) 4 (8%)
 Asian 1 (2%) 0
Median plasma HIV-1 RNA, log10 copies/mL 4.96 4.82
 ≥100,000 copies/mL, n (%) 22 (43%) 20 (40%)
Median CD4 cell count, cells/mm3 (range) 237.0 (19–1061) 272.5 (19–699)
 <200 cells/mm3, n (%) 21 (41%) 17 (34%)
 <50 cells/mm3, n (%) 3 (6%) 7 (14%)
Positive hepatitis C serology 5 (10%) 5 (10%)
CDC classification for HIV infection, n (%)   
 Category A 40 (78%) 43 (86%)
 Category B 4 (8%) 7 (14%)
 Category C 7 (14%) 0
Framingham risk score <5%*, n (%) 28 (78%) 28 (88%)
Diabetes type II, n (%) 3 (6%) 1 (2%)
Hypercholesterolemia, n (%) 17 (33%) 14 (28%)
Hypertension, n (%) 9 (18%) 12 (24%)
Tobacco use   
 Never smoked, n (%) 26 (51%) 19 (38%)
 Current smoker, n (%) 20 (39%) 20 (40%)
 Former smoker, n (%) 5 (10%) 11 (22%)
 Years smoked, median (range) 10 (2–39) 10 (0–33)
  1. *FPV/r, n = 36; EFV, n = 32. Framingham scores were calculated only in non-diabetic individuals aged 30 years or older. FPV/r, n = 24; EFV, n = 30.
  2. Abbreviations: ABC/3TC abacavir/lamivudine, CDC Centers for Disease Control and Prevention, EFV efavirenz, FPV/r fosamprenavir/ritonavir.